234 related articles for article (PubMed ID: 27639695)
1. Input analysis for two public consultations on the EU Clinical Trials Regulation.
Langhof H; Lander J; Strech D
Health Res Policy Syst; 2016 Sep; 14(1):69. PubMed ID: 27639695
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the influence of the tobacco industry on EU governance: automated content analysis of the EU Tobacco Products Directive.
Costa H; Gilmore AB; Peeters S; McKee M; Stuckler D
Tob Control; 2014 Nov; 23(6):473-8. PubMed ID: 25124165
[TBL] [Abstract][Full Text] [Related]
3. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
[TBL] [Abstract][Full Text] [Related]
4. Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries.
Hartmann M
Trials; 2012 Apr; 13():53. PubMed ID: 22540886
[TBL] [Abstract][Full Text] [Related]
5. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
6. Modern regulatory impact analysis: the experience of the European Union.
Ballantine B; Devonald B
Regul Toxicol Pharmacol; 2006 Feb; 44(1):57-68. PubMed ID: 16307835
[TBL] [Abstract][Full Text] [Related]
7. The EU Clinical Trials Regulation: key priorities, purposes and aims and the implications for public health.
Flear ML
J Med Ethics; 2016 Mar; 42(3):192-8. PubMed ID: 26831742
[TBL] [Abstract][Full Text] [Related]
8. Cross-sector cooperation in health-enhancing physical activity policymaking: more potential than achievements?
Hämäläinen RM; Aro AR; Lau CJ; Rus D; Cori L; Syed AM;
Health Res Policy Syst; 2016 Apr; 14(1):33. PubMed ID: 27129850
[TBL] [Abstract][Full Text] [Related]
9. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
Dreier G; Marx C; Schmoor C; Maier-Lenz H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
[TBL] [Abstract][Full Text] [Related]
10. An anthropological analysis of European Union (EU) health governance as biopolitics: the case of the EU tissues and cells directive.
Hoeyer K
Soc Sci Med; 2010 Jun; 70(12):1867-1873. PubMed ID: 20378227
[TBL] [Abstract][Full Text] [Related]
11. Prospects for public participation on nuclear risks and policy options: innovations in governance practices for sustainable development in the European Union.
O'Connor M; van den Hove S
J Hazard Mater; 2001 Sep; 86(1-3):77-99. PubMed ID: 11532360
[TBL] [Abstract][Full Text] [Related]
12. EU accession: A policy window opportunity for nursing?
De Raeve P; Rafferty AM; Bariball L; Young R; Boiko O
Health Policy; 2017 Mar; 121(3):292-299. PubMed ID: 28162814
[TBL] [Abstract][Full Text] [Related]
13. Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries.
Ostuzzi G; Gastaldon C; Petrini C; Godman B; Barbui C
Epidemiol Psychiatr Sci; 2020 May; 29():e126. PubMed ID: 32370820
[TBL] [Abstract][Full Text] [Related]
14. The European clinical trials regulation (No 536/2014): changes and challenges.
Scavone C; di Mauro G; Pietropaolo M; Alfano R; Berrino L; Rossi F; Tomino C; Capuano A
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1027-1032. PubMed ID: 31608706
[No Abstract] [Full Text] [Related]
15. Clinical ethics consultation among Italian ethics committee: A mixed method study.
De Panfilis L; Merlo DF; Satolli R; Perin M; Ghirotto L; Costantini M
PLoS One; 2019; 14(12):e0226710. PubMed ID: 31887158
[TBL] [Abstract][Full Text] [Related]
16. Application challenges of the new EU Clinical Trials Regulation.
Gefenas E; Cekanauskaite A; Lekstutiene J; Lukaseviciene V
Eur J Clin Pharmacol; 2017 Jul; 73(7):795-798. PubMed ID: 28567502
[TBL] [Abstract][Full Text] [Related]
17. Complex governance structures and incoherent policies: Implementing the EU water framework directive in Sweden.
Söderberg C
J Environ Manage; 2016 Dec; 183():90-97. PubMed ID: 27576152
[TBL] [Abstract][Full Text] [Related]
18. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
Borup R; Traulsen JM; Kaae S
Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
[TBL] [Abstract][Full Text] [Related]
19. Revision of the EU Bathing Water Directive: economic costs and benefits.
Georgiou S; Bateman IJ
Mar Pollut Bull; 2005 Apr; 50(4):430-8. PubMed ID: 15823305
[TBL] [Abstract][Full Text] [Related]
20. What is good governance in the context of drug policy?
Singleton N; Rubin J
Int J Drug Policy; 2014 Sep; 25(5):935-41. PubMed ID: 24768218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
